Non-Hormonal Drug Reduced Hot Flashes From Endocrine Therapy for Breast Cancer

Menopause Drug Reduces Breast Cancer Growth In Clinical Trial

A drug used to relieve the debilitating symptoms of menopause may also be reducing the risk of invasive breast cancer, a new clinical trial by Northwestern University suggests. Almost 60,000 women a year are diagnosed with a contained form of breast cancer that can indicate a higher risk of developing invasive tumors later in life.The non-invasive cancer is typically detected during routine mammograms, accounts for up to 25 percent of all br…

Study: Elinzanetant cuts vasomotor symptoms in women with breast cancer on endocrine therapy

For women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for hormone receptor (HR)-positive breast cancer, elinzanetant, a neurokinin-targeted therapy, reduces the frequency of vasomotor symptoms, according to a study published online June 2 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.

Non-Hormonal Drug Reduced Hot Flashes From Endocrine Therapy for Breast Cancer

(MedPage Today) -- CHICAGO -- The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women receiving endocrine therapy for hormone receptor (HR)-positive breast cancer or its prevention, the phase...

Elinzanetant found to reduce VMS from endocrine therapy for breast cancer

A phase 3 trial shows elinzanetant effectively reduces hot flashes and improves quality of life in patients undergoing hormone therapy for hormone-receptor-positive breast cancer.